What is the recommended approach to evaluate and manage microscopic hematuria?

Approach to Microscopic Hematuria

Confirm microscopic hematuria with ≥3 RBCs/HPF on microscopic examination of urinary sediment from 2 of 3 properly collected clean-catch midstream specimens, not just dipstick alone. 1

Initial Confirmation and Exclusion of Benign Causes

• Always confirm dipstick hematuria with microscopic urinalysis - dipstick has only 65-99% specificity and cannot be relied upon alone 1
• Before proceeding with evaluation, exclude transient benign causes and repeat urinalysis 48 hours after cessation:
  • Menstruation
  • Vigorous exercise
  • Sexual activity
  • Viral illness
  • Trauma
  • Urinary tract infection (treat and recheck in 6 weeks) 1

Risk Stratification for Urologic Evaluation

Use the 2025 AUA/SUFU risk stratification system to determine evaluation intensity 2:

Low/Negligible Risk (0-0.4% malignancy risk) - ALL criteria must be met:

• 3-10 RBCs/HPF on single urinalysis
• Age: Women <50 years OR Men <40 years
• Never smoker or <10 pack-years
• No additional risk factors for urothelial cancer

Intermediate Risk (0.2-3.1% malignancy risk) - ONE or more:

• 11-25 RBCs/HPF on single urinalysis
• Age: Women 50-59 years OR Men 40-59 years
• 10-30 pack-years smoking history
• Previously low-risk patient with 3-10 RBCs/HPF on repeat urinalysis

High Risk (1.3-6.3% malignancy risk) - ONE or more:

• 25 RBCs/HPF on single urinalysis

• Age: Women or Men ≥60 years

• 30 pack-years smoking history

• History of gross hematuria
• Occupational exposure to chemicals/dyes (benzenes, aromatic amines)
• History of pelvic radiation
• History of cyclophosphamide use
• Chronic indwelling foreign body
• History of irritative voiding symptoms
• Recurrent UTIs despite appropriate antibiotics 1, 2

Evaluation for Renal Parenchymal Disease FIRST

Before proceeding with urologic workup, evaluate for glomerular/renal disease if ANY of the following are present 1:

• Significant proteinuria: >1,000 mg/24 hours (or >500 mg/24 hours if persistent/increasing)
• Red cell casts (virtually pathognomonic for glomerular bleeding)
• Elevated serum creatinine (based on age/sex-specific normal ranges)
• Dysmorphic RBCs: >80% dysmorphic suggests glomerular origin 1

If any of these are present, refer to nephrology or evaluate for primary renal disease rather than proceeding with urologic evaluation. The presence of these findings indicates renal parenchymal disease requiring different management. 1

Urologic Evaluation Based on Risk Category

Low/Negligible Risk Patients:

• Shared decision-making regarding:
  • Repeat urinalysis in 6 months, OR
  • Proceed with cystoscopy + renal/bladder ultrasound 2, 3
• If repeat UA negative, discharge from care
• If repeat UA shows persistent hematuria (3-25 RBCs/HPF), reclassify as intermediate risk

Intermediate Risk Patients:

• Cystoscopy (flexible preferred for patient comfort)
• Upper tract imaging: Renal ultrasound or CT urogram without contrast 2, 3
• If negative evaluation: repeat urinalysis at 12 months
• If persistent hematuria at 12 months: shared decision-making for further evaluation

High Risk Patients:

• Cystoscopy (mandatory - bladder cancer is most common malignancy detected) 1
• Axial upper tract imaging: CT urogram (preferred) or MR urogram
  • Start with noncontrast scan
  • If urolithiasis found in low-risk patient, may stop
  • Otherwise, proceed with IV contrast 1, 2
• Consider urine cytology (detects high-grade tumors and carcinoma in situ, though insensitive for low-grade lesions) 1

Critical Cystoscopy Guidance

Perform cystoscopy in ALL patients >40 years old and in patients <40 years with risk factors for bladder cancer 1. This includes patients where upper tract imaging reveals a potentially benign source - upper and lower tract pathologies often coexist. 4

• Cystoscopy may be deferred in patients <40 years with NO risk factors, but perform urine cytology instead 1
• Flexible cystoscopy causes less pain, has fewer post-procedure symptoms, and has equivalent or superior diagnostic accuracy compared to rigid cystoscopy 1

Follow-Up After Negative Initial Evaluation

For patients with negative initial evaluation, follow-up intensity depends on risk category 1, 2:

• Low-risk patients: Discharge from care if repeat UA negative
• Intermediate/High-risk patients:
  • Repeat urinalysis at 6,12,24, and 36 months
  • Consider repeat cytology (detects high-grade tumors even if insensitive for low-grade)
  • Monitor blood pressure

Immediate re-evaluation with cystoscopy, cytology, or imaging if ANY of the following occur 1:

1. Gross hematuria develops
2. Abnormal urinary cytology
3. Irritative voiding symptoms without infection

After 3 years of negative surveillance, discontinue urologic monitoring unless new symptoms develop. 1

Common Pitfalls to Avoid

• Don't rely on dipstick alone - 35% false positive rate requires microscopic confirmation 1
• Don't skip renal disease evaluation - missing proteinuria, casts, or elevated creatinine leads to delayed nephrology referral for treatable conditions 1
• Don't defer cystoscopy in high-risk patients even with benign imaging - bladder cancer is the most common malignancy and imaging doesn't exclude it 1, 4
• Don't over-evaluate low-risk patients - women <50 and men <40 with minimal hematuria and no risk factors have <0.4% malignancy risk 2
• Don't under-evaluate persistent hematuria - bladder cancer can be diagnosed years after initial hematuria appearance, particularly in high-risk groups 1

Important note: The 2025 guidelines effectively stratify risk for urothelial cancer but do NOT reliably predict renal cortical neoplasms - the same risk factors don't apply to kidney masses. 5 This means upper tract imaging serves primarily to detect stones and anatomic abnormalities rather than to risk-stratify for renal tumors.